CAR-T Archives

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 29 May 2015

Pfizer to Control Cellectis in a €1.5 Billion Deal?

Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers. According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person […]

May 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 13 May 2015

[UPDATE] Adaptimmune raised €156.7M in its IPO

Oxford-based Adaptimmune has launched its IPO on NASDAQ, where the immunotherapist plans to raise about €156.7M. The company is focused on novel cancer immunotherapy products based on T-cell receptors. [UPDATE]: The company successfully raised the quantity expected. Adaptimmune is focused on the use of T-cell therapy to treat cancer. It aims to utilise the body’s own machinery, T […]

May 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 May 2015

US-based Juno Therapeutics purchased a German biotech

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer. The transaction further underlines Juno’s strategy of becoming a world leader in process development and in […]

May 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Apr 2015

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Just a week after announcing its intention to launch an IPO in the United States, Cardio3 Biosciences continues increasing its presence in the States. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a significant patent application broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen […]

April 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Apr 2015

Gene editing to make French fries less unhealthy

A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an average of €126M on the development of a genetically engineered crop (GMO), including €32M in regulatory costs. The Agriculture Department once takes two to five years to review applications, though it is trying to reduce that to 13 to 16 […]

April 6, 2015 - 4 minutesmins - By Cédric Brock

News and Trends 31 Mar 2015

Merck Serono and Intrexon, to develop CAR-T Therapy

Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, […]

March 31, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Mar 2015

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]

March 26, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 21 Jan 2015

Review: The CRISPR’s Therapeutical revolution

Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex CRISPR-Cas9 (CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR associated nuclease). “Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci ” Brouns, S. J. J., et al. (2008). The CRISPR repeat sequence has […]

January 21, 2015 - 4 minutesmins - By Cédric Brock

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

[Update] AstraZeneca to buy a CAR-T expert?

Pfizer to Control Cellectis in a €1.5 Billion Deal?

[UPDATE] Adaptimmune raised €156.7M in its IPO

US-based Juno Therapeutics purchased a German biotech

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Gene editing to make French fries less unhealthy

Merck Serono and Intrexon, to develop CAR-T Therapy

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Review: The CRISPR’s Therapeutical revolution

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!